Last updated: August 30, 2026
Oxaliplatin is a mature platinum-based chemotherapy with no meaningful remaining U.S. exclusivity. Sanofi’s Eloxatin franchise lost commercial protection after patent expiry and generic entry, shifting the market from branded pricing to hospital procurement, sterile-injectable supply, and clinical protocol demand. Revenue growth is now volume-driven and concentrated in colorectal cancer treatment, particularly FOLFOX and related regimens.
What is oxaliplatin and how is it used clinically?
Oxaliplatin is a platinum-based antineoplastic agent marketed originally as Eloxatin. It forms DNA crosslinks and inhibits DNA replication. The drug is administered intravenously and is generally used in combination with fluorouracil and leucovorin.
The main FDA-approved uses are:
| Indication |
Common regimen |
Commercial relevance |
| Adjuvant treatment of stage III colon cancer |
FOLFOX |
High-volume institutional use |
| Metastatic colorectal cancer |
FOLFOX or FOLFOX-based combinations |
Core demand driver |
| Advanced colorectal cancer after progression |
Combination therapy with fluorouracil and leucovorin |
Established use |
| Other gastrointestinal cancers |
Off-label or guideline-supported use |
Smaller, variable demand |
Oxaliplatin is particularly associated with FOLFOX, which combines oxaliplatin, leucovorin, fluorouracil, and a fluorouracil infusion. CAPOX, which combines oxaliplatin with oral capecitabine, is another important treatment platform.
The principal dose-limiting adverse event is cumulative peripheral sensory neuropathy. Hypersensitivity reactions, myelosuppression, nausea, diarrhea, and hepatotoxicity also affect treatment duration and utilization. Neuropathy can limit the number of cycles, reducing the relationship between patient volume and milligram demand.
When did oxaliplatin receive FDA approval?
The FDA approved Eloxatin in August 2002 for use with fluorouracil and leucovorin in advanced colorectal cancer. The agency later approved adjuvant treatment for stage III colon cancer in 2004 based on evidence supporting FOLFOX in patients following surgical resection.[1]
Oxaliplatin originated from Debiopharm and was developed commercially by Sanofi, then Sanofi-Synthelabo. The original U.S. product was supplied as a lyophilized powder for reconstitution, followed by generic oxaliplatin injection products.
FDA regulatory status
Oxaliplatin remains an FDA-approved active pharmaceutical ingredient. The market consists primarily of abbreviated new drug application products and institutional-use injectable products. The original Eloxatin brand has limited commercial importance compared with generic versions.
The FDA regulatory profile is mature:
- New chemical entity approval: 2002
- Adjuvant colon-cancer approval: 2004
- Generic injectable competition: established after patent expiry
- Current market structure: multisource generic
- Biologic classification: not applicable
- Biosimilar pathway: not applicable
Oxaliplatin is a small-molecule drug, so competitors file ANDAs rather than abbreviated biologics applications. Biosimilar risk does not apply.
What patents protected Eloxatin and when did oxaliplatin lose exclusivity?
The principal U.S. composition patent associated with oxaliplatin was U.S. Patent No. 5,716,988, covering optically pure oxaliplatin-related platinum compounds. The patent was assigned to Debiopharm and licensed for commercial development.[2]
| Patent or regulatory right |
Relevance |
Approximate end of protection |
| U.S. Patent No. 5,716,988 |
Core oxaliplatin composition patent |
August 2015 |
| FDA five-year NCE exclusivity |
Restricted ANDA submission based on the active ingredient |
2007 |
| Pediatric extension, if applicable |
Potential six-month extension to listed rights |
2016 |
| Formulation and manufacturing rights |
Product-specific or process-specific protection |
Varied by jurisdiction |
The core patent term, rather than FDA exclusivity, determined the timing of broad U.S. generic entry. By the mid-2010s, oxaliplatin had transitioned into a mature generic market.
Patent expiration dates can vary by jurisdiction, patent-term adjustments, patent-term extensions, pediatric extensions, and listed patents. The FDA Orange Book is the primary source for U.S. patents and regulatory exclusivity associated with approved products.[3]
How many patents cover oxaliplatin today?
No single patent number defines the current global oxaliplatin market. The original active-ingredient protection has expired in the United States, Europe, and other major markets. Remaining patents may cover specific formulations, manufacturing methods, combinations, dosing schedules, or delivery systems, but these rights generally do not restore broad exclusivity over oxaliplatin itself.
What formulations are protected by oxaliplatin patents?
Potential secondary patent categories include:
- Stabilized aqueous oxaliplatin solutions
- Lyophilized injectable formulations
- Specific excipient systems
- Container-closure configurations
- Manufacturing and purification processes
- Combination regimens with fluorouracil, leucovorin, or capecitabine
- Dosing schedules intended to reduce neuropathy
- Regional or hospital-specific delivery technologies
These patents have limited commercial effect unless they block the formulation used by an ANDA applicant or create a legally enforceable distinction from the reference product. Generic oxaliplatin products can generally compete through standard injectable presentations without infringing expired composition claims.
Which companies compete in the oxaliplatin market?
The branded market was led by Sanofi. The generic market includes multiple injectable-drug manufacturers, with availability varying by country and procurement channel.
Relevant suppliers have included:
- Sanofi, through Eloxatin
- Teva Pharmaceuticals
- Fresenius Kabi
- Sandoz and other Novartis-related generic operations
- Pfizer and Hospira-related injectable operations
- Accord Healthcare
- Hikma Pharmaceuticals
- Dr. Reddy’s Laboratories
- Sun Pharmaceutical Industries
- Regional hospital-injectable manufacturers
Supplier participation differs between the United States, Europe, Asia, and emerging markets. A company may hold an FDA approval without maintaining substantial commercial share. Hospital group purchasing organizations, wholesaler contracts, and manufacturing capacity have greater impact than historical brand recognition.
How does oxaliplatin compare with competing platinum drugs?
| Drug |
Primary use profile |
Key commercial advantage |
Key limitation |
| Oxaliplatin |
Colorectal and gastrointestinal cancers |
Core component of FOLFOX and CAPOX |
Cumulative neuropathy |
| Cisplatin |
Broad solid-tumor use |
Low cost and extensive clinical experience |
Nephrotoxicity, ototoxicity, emesis |
| Carboplatin |
Ovarian, lung, and other cancers |
More favorable tolerability than cisplatin in many settings |
Myelosuppression |
| Irinotecan |
Colorectal cancer, especially FOLFIRI |
Alternative backbone to oxaliplatin |
Diarrhea and neutropenia |
| Capecitabine |
Oral fluoropyrimidine partner |
Oral administration in CAPOX |
Hand-foot syndrome and adherence issues |
Oxaliplatin competes most directly with irinotecan in colorectal-cancer treatment. FOLFOX and FOLFIRI are complementary and substitutable depending on treatment line, toxicity profile, disease characteristics, and physician preference.
What was the financial trajectory of Eloxatin?
Eloxatin generated substantial branded revenue during its protected period because it became a standard component of colorectal-cancer treatment. Sanofi reported Eloxatin sales in the billion-euro range during the franchise’s peak period, supported by increased adoption of FOLFOX and expanded use in adjuvant colon cancer.[4]
The financial trajectory followed four stages:
| Stage |
Period |
Financial characteristics |
| Launch and clinical adoption |
2002-2004 |
Rapid uptake following metastatic and adjuvant approvals |
| Peak branded commercialization |
Mid-2000s to early 2010s |
High pricing and broad FOLFOX utilization |
| Patent litigation and generic preparation |
Late 2000s to mid-2010s |
Generic-entry risk affected forecasts and contracting |
| Post-expiry generic market |
Mid-2010s onward |
Sharp price compression and volume-based economics |
Brand revenue declined after generic competition. The decline was driven by lower unit prices, hospital substitution, and reduced negotiating leverage. Sanofi’s economics shifted from product-level exclusivity to portfolio management and oncology franchise replacement.
Public-company revenue reporting often grouped Eloxatin with broader oncology or pharmaceutical segments, making precise current product-level revenue difficult to isolate. No single audited global market figure captures all oxaliplatin sales because hospital contracts, government tenders, distributor sales, and regional generic suppliers report the product differently.
What generic entry risks exist for oxaliplatin?
Generic-entry risk is no longer an impending event in the United States. It is an established market condition.
The main effects are:
- Price erosion after multisource entry.
- Substitution of brand supply by hospital pharmacies.
- Greater reliance on wholesaler and group-purchasing contracts.
- Lower gross margins for manufacturers.
- Procurement pressure during supply disruptions.
- Reduced value for formulation patents that do not block standard injectable presentations.
Oxaliplatin is a sterile injectable, so manufacturing barriers remain meaningful even after patent expiry. The drug requires validated aseptic processing, controlled facilities, regulatory compliance, and reliable supply of active pharmaceutical ingredient. These barriers can limit the number of dependable suppliers, even when many companies hold approvals.
What manufacturing and IP barriers affect oxaliplatin?
The commercial barriers are operational rather than exclusivity-based:
- Sterile manufacturing capacity
- Quality-system compliance
- Batch-release testing
- Supply of platinum-containing API
- Container and vial availability
- Hospital tender qualification
- Inventory requirements for oncology centers
- Regulatory inspection performance
- Ability to maintain uninterrupted supply
These factors can support temporary price increases during shortages, but they do not create durable patent-like pricing power.
What patent litigation affected oxaliplatin?
Sanofi and related entities faced generic challenges to Eloxatin patent rights during the period preceding broad generic competition. Paragraph IV filings against listed patents created litigation exposure for applicants seeking earlier market entry under the Hatch-Waxman Act.
The litigation pattern was commercially important because the outcome could affect whether generic manufacturers launched before the listed patent expiry date. Once the core U.S. patent term ended and multiple suppliers entered, the strategic value of continued litigation declined.
Current litigation risk is more likely to involve:
- ANDA formulation disputes
- Manufacturing-process patents
- Product labeling and method-of-use claims
- Supply contracts
- Antitrust or procurement disputes
- Patent challenges in individual foreign jurisdictions
The Orange Book remains the operative source for U.S. listed patents, while the FDA’s Drugs@FDA database provides approval and labeling records.[3,5]
What is the Orange Book status of oxaliplatin?
The Orange Book historically listed Eloxatin and associated patent information. The commercial significance of the listed composition patent has ended following expiration. Generic oxaliplatin products compete through ANDAs and therapeutic equivalence determinations.
The practical Orange Book assessment is:
- Core composition protection: expired
- NCE exclusivity: expired
- Broad generic substitution: established
- Active brand premium: limited
- Method-of-use exposure: generally manageable through labeling strategy
- Biosimilar provisions: irrelevant
A generic applicant’s commercial risk now centers on FDA approval, manufacturing reliability, and contracting rather than a fundamental composition-patent barrier.
What is the geographic coverage of oxaliplatin patents and sales?
Oxaliplatin has global clinical use, but patent and pricing outcomes differ sharply by region.
| Region |
Patent position |
Market structure |
| United States |
Core protection expired |
Multisource injectable generics |
| European Union |
Core protection expired |
National tendering and generic competition |
| Japan |
Mature product with local regulatory history |
Generic and institutional procurement |
| China |
Large oncology demand base |
Domestic manufacturers and tender pricing |
| India |
Strong generic manufacturing base |
Price-sensitive, competitive market |
| Latin America |
Variable local rights and registration |
Public tenders and branded generics |
| Middle East and Africa |
Import and registration dependent |
Distributor-led supply |
The United States generally provides the largest opportunity for regulated injectable pricing, but it also has substantial contracting pressure. Emerging markets can generate volume but usually deliver lower net prices.
How strong is the oxaliplatin patent estate?
The patent estate is weak for broad product exclusivity and moderate for narrow technical claims.
| Dimension |
Assessment |
| Core molecule protection |
Expired |
| Regulatory exclusivity |
Expired |
| Formulation protection |
Narrow and product-dependent |
| Method-of-use protection |
Limited commercial blocking power |
| Manufacturing patents |
Potentially relevant but avoidable |
| Biosimilar protection |
Not applicable |
| Generic substitution risk |
High |
| Supply-chain barrier |
Moderate |
| Long-term branded pricing power |
Low |
The remaining defensibility of an oxaliplatin business depends on manufacturing quality, supply continuity, formulation differentiation, and distribution reach. Patent ownership alone is unlikely to support premium valuation.
What is the outlook for oxaliplatin revenue?
The market should remain stable in volume but structurally weak in price. Demand is supported by the global incidence of colorectal cancer and continued use of FOLFOX and CAPOX. The World Health Organization identifies colorectal cancer as one of the most commonly diagnosed cancers worldwide, supporting a large underlying treatment population.[6]
Revenue growth is likely to come from:
- Rising colorectal-cancer incidence
- Greater oncology access in emerging markets
- Expansion of hospital chemotherapy capacity
- Increased use in adjuvant treatment
- New regional registrations
- Supply shortages affecting short-term pricing
Revenue pressure will come from:
- Generic tendering
- Hospital purchasing consolidation
- Treatment de-escalation to reduce neuropathy
- Alternative FOLFIRI-based regimens
- Oral capecitabine substitution in selected settings
- Manufacturing competition
- Fixed-dose or cycle-limiting treatment protocols
For manufacturers, oxaliplatin is a scale and reliability product rather than a high-margin innovation asset. For investors, the key variables are injectable capacity, contract retention, shortage exposure, and geographic mix.
Key Takeaways
- Oxaliplatin is a mature generic chemotherapy centered on FOLFOX and CAPOX.
- Sanofi’s Eloxatin franchise achieved major revenue during the protected adoption period.
- The principal U.S. composition patent, U.S. Patent No. 5,716,988, expired around 2015.
- FDA exclusivity and broad patent barriers have ended.
- Paragraph IV litigation was relevant before generic entry but has limited current strategic importance.
- Biosimilar risk does not apply because oxaliplatin is a small molecule.
- The current market is driven by hospital tenders, sterile manufacturing, supply continuity, and price.
- Demand should remain resilient because colorectal cancer incidence and FOLFOX utilization remain substantial.
- Long-term revenue growth is likely to be volume-led, while net pricing remains under pressure.
FAQs About Oxaliplatin Commercialization and IP
Is Eloxatin still commercially important?
Eloxatin retains clinical recognition, but generic oxaliplatin has displaced the brand in many institutional markets. Commercial value is concentrated in generic supply contracts rather than branded pricing.
Can a new oxaliplatin formulation receive patent protection?
Yes. A novel formulation, delivery system, manufacturing process, or dosing method may qualify for patent protection if it meets statutory novelty, nonobviousness, and enablement requirements. Such rights would not automatically restore exclusivity over standard oxaliplatin.
Does oxaliplatin have a 180-day generic exclusivity period?
A first ANDA applicant may qualify for 180-day exclusivity if it satisfies the statutory requirements and maintains eligibility. The effect is product- and litigation-specific. Broad market exclusivity has already ended.
Which cancer drugs most directly threaten oxaliplatin demand?
Irinotecan-based FOLFIRI is the principal regimen-level competitor in colorectal cancer. Carboplatin and cisplatin compete in other tumor types but are not direct substitutes across all oxaliplatin indications.
Can oxaliplatin shortages increase generic manufacturer margins?
Yes, temporary shortages can increase contract value or spot pricing. The effect is usually short-lived because additional suppliers, imports, or procurement changes can restore competition.
References
-
U.S. Food and Drug Administration. (2002). Eloxatin approval history and prescribing information. Drugs@FDA.
-
United States Patent and Trademark Office. (1998). U.S. Patent No. 5,716,988: Optically pure cis-oxalato(trans-l)-1,2-diaminocyclohexane platinum (II).
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
-
Sanofi. (2008). Annual report 2008. Sanofi.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database.
-
World Health Organization. (2024). Colorectal cancer. World Health Organization.
